Floatz logo

Therapeutic Asset Ratings

209 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Itc-6146Ro
Non-Small Cell Lung Carcinoma
IntoCell, IncP1C (36)
Itil-168
Non-Small Cell Lung Carcinoma
Instil BioP1C (36)
Itil-306
Non-Small Cell Lung Carcinoma
Instil BioP1C (36)
ly3962673
Non-Small Cell Lung Carcinoma
Eli Lilly and CompanyP1C (36)
ly4050784
Non-Small Cell Lung Carcinoma
Eli Lilly and CompanyP1C (36)
ly4052031
Non-Small Cell Lung Carcinoma
Eli Lilly and CompanyP1C (36)
ly4066434.
Non-Small Cell Lung Carcinoma
Eli Lilly and CompanyP1C (36)
ly4101174
Non-Small Cell Lung Carcinoma
Eli Lilly and CompanyP1C (36)
lyl797
Non-Small Cell Lung Carcinoma
Lyell Immunopharma, Inc.P1C (36)
lyl845
Non-Small Cell Lung Carcinoma
Lyell Immunopharma, Inc.P1C (36)
mgy825
Non-Small Cell Lung Carcinoma
Novartis PharmaceuticalsP1C (36)
Mrtx1133
Non-Small Cell Lung Carcinoma
Mirati Therapeutics Inc.P1C (36)
ngm831
Non-Small Cell Lung Carcinoma
NGM Biopharmaceuticals, IncP1C (36)
NT-112
Non-Small Cell Lung Carcinoma
AstraZenecaP1C (36)
Optimized Neoantigen Synthetic Long Peptide Vaccine
Non-Small Cell Lung Carcinoma
Washington University School of MedicineP1C (36)
pf-08046049
Non-Small Cell Lung Carcinoma
Seagen, a wholly owned subsidiary of PfizerP1C (36)
PIMITESPIB
Non-Small Cell Lung Carcinoma
Taiho Pharmaceutical Co., Ltd.P1C (36)
qlh11811
Non-Small Cell Lung Carcinoma
Qilu Pharmaceutical Co., Ltd.P1C (36)
qls5316
Non-Small Cell Lung Carcinoma
Qilu Pharmaceutical Co., Ltd.P1C (36)
RC198
Non-Small Cell Lung Carcinoma
RemeGen Co., Ltd.P1C (36)
ro7515629
Non-Small Cell Lung Carcinoma
Hoffmann-La RocheP1C (36)
sm08502
Non-Small Cell Lung Carcinoma
Biosplice Therapeutics, Inc.P1C (36)
Tas-102
Non-Small Cell Lung Carcinoma
Taiho Pharmaceutical Co., Ltd.P1C (36)
Tas-115
Non-Small Cell Lung Carcinoma
Taiho Pharmaceutical Co., Ltd.P1C (36)
tas2940
Non-Small Cell Lung Carcinoma
Taiho Oncology, Inc.P1C (36)
Showing 176 to 200 of 209 assets
PreviousPage 8 of 9Next